COVID-19 induces a robust, extended inflammatory “cytokine storm” that contributes to an increased morbidity and mortality, particularly in patients with type 2 diabetes (T2D). Macrophages are a key innate immune cell population responsible for the cytokine storm that has been shown, in T2D, to promote excess inflammation in response to infection. Using peripheral monocytes and … Continue reading #Coronavirus induces #diabetic macrophage-mediated inflammation via SETDB2
Tag: Diabetes
Premature death from all causes and cardiovascular disease (CVD) causes is higher among persons with diabetes. Objective To investigate the association between time spent cycling and all-cause and CVD mortality among persons with diabetes, as well as to evaluate the association between change in time spent cycling and risk of all-cause and CVD mortality. Design, … Continue reading Association of #Cycling With All-Cause and #Cardiovascular Disease Mortality Among Persons With #DiabetesThe European Prospective Investigation Into Cancer and Nutrition (EPIC) Study
To examine whether glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i) are preferentially initiated among patients with cardiovascular disease, heart failure (HF), or nephropathy, where these drug classes have established benefit, compared with dipeptidyl peptidase 4 inhibitors (DPP-4i), for which corresponding benefits have not been demonstrated. RESEARCH DESIGN AND METHODS We … Continue reading Second-Line Therapy for Type 2 #Diabetes Management: The Treatment/Benefit Paradox of #Cardiovascular and #Kidney Comorbidities
Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results when communicating the benefits of this class of drug to patients. Objective To estimate … Continue reading Extrapolating Long-term Event-Free and Overall Survival With #Dapagliflozin in Patients With #Heart Failure and Reduced #Ejection Fraction
